Literature DB >> 21220996

Soluble form of the receptor for advanced glycation end products is a marker of acute lung injury but not of severe sepsis in critically ill patients.

Matthieu Jabaudon1, Emmanuel Futier, Laurence Roszyk, Elodie Chalus, Renaud Guerin, Antoine Petit, Segolene Mrozek, Sebastien Perbet, Sophie Cayot-Constantin, Christian Chartier, Vincent Sapin, Jean-Etienne Bazin, Jean-Michel Constantin.   

Abstract

OBJECTIVES: Levels of the soluble form of the receptor for advanced glycation end products (sRAGE) are elevated during acute lung injury. However, it is not known whether this increase is linked to its involvement in alveolar epithelium injury or in systemic inflammation. Whether sRAGE is a marker of acute lung injury and acute respiratory distress syndrome, regardless of associated severe sepsis or septic shock, remains unknown in the intensive care unit setting.
DESIGN: Prospective, observational, clinical study.
SETTING: Intensive care unit of an academic medical center. PATIENTS: A total of 64 consecutive subjects, divided into four groups: acute lung injury/acute respiratory distress syndrome (n=15); acute lung injury/acute respiratory distress syndrome plus severe sepsis/septic shock (n=18); severe sepsis/septic shock (n=16); and mechanically ventilated controls (n=15).
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Plasma sRAGE levels were measured at baseline and on days 3, 6, and 28 (or at intensive care unit discharge, whichever occurred first). Baseline plasma levels of sRAGE were significantly higher in patients with acute lung injury/acute respiratory distress syndrome, with (median, 2951 pg/mL) or without (median, 3761 pg/mL) severe sepsis, than in patients with severe sepsis (median, 488 pg/mL) only and in mechanically ventilated controls (median, 525 pg/mL). Levels of sRAGE were correlated with acute lung injury/acute respiratory distress syndrome severity and decreased over time but were not associated with outcome. Lower baseline plasma sRAGE was associated with focal loss of aeration based on computed tomography lung morphology.
CONCLUSIONS: sRAGE levels were elevated during acute lung injury/acute respiratory distress syndrome, regardless of the presence or absence of severe sepsis. The plasma level of sRAGE was correlated with clinical and radiographic severity in acute respiratory distress syndrome patients and decreased over time, suggesting resolution of the injury to the alveolar epithelium. Further study is warranted to test the clinical utility of this biomarker in managing such patients and to better understand its relationship with lung morphology during acute lung injury/acute respiratory distress syndrome.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21220996     DOI: 10.1097/CCM.0b013e318206b3ca

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  49 in total

Review 1.  The receptor for advanced glycation end products and acute lung injury/acute respiratory distress syndrome.

Authors:  Weidun Alan Guo; Paul R Knight; Krishnan Raghavendran
Journal:  Intensive Care Med       Date:  2012-07-10       Impact factor: 17.440

2.  Plasma levels of soluble receptor for advanced glycation end products in patients with acute respiratory distress syndrome.

Authors:  Weili Gu; Zhihua Xu; Feng Qi; Zhihui Sang; Chunhua Wang; Feng Li
Journal:  Int J Clin Exp Med       Date:  2014-12-15

3.  Expression of the receptor for advanced glycation end-products and frequency of polymorphism in lung cancer.

Authors:  Hongmei Wang; Yongchun Li; Wencheng Yu; Liqing Ma; Xia Ji; Wei Xiao
Journal:  Oncol Lett       Date:  2015-05-12       Impact factor: 2.967

4.  Effects of a recruitment maneuver on plasma levels of soluble RAGE in patients with diffuse acute respiratory distress syndrome: a prospective randomized crossover study.

Authors:  Matthieu Jabaudon; Nacim Hamroun; Laurence Roszyk; Renaud Guérin; Jean-Etienne Bazin; Vincent Sapin; Bruno Pereira; Jean-Michel Constantin
Journal:  Intensive Care Med       Date:  2015-03-20       Impact factor: 17.440

5.  Genomic and Genetic Approaches to Deciphering Acute Respiratory Distress Syndrome Risk and Mortality.

Authors:  Heather Lynn; Xiaoguang Sun; Nancy Casanova; Manuel Gonzales-Garay; Christian Bime; Joe G N Garcia
Journal:  Antioxid Redox Signal       Date:  2019-06-18       Impact factor: 8.401

6.  The diagnostic utility and tendency of the soluble receptor for advanced glycation end products (sRAGE) in exudative pleural effusion.

Authors:  Yun Su Sim; Dong Gyu Kim; Tae Rim Shin
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

Review 7.  Tidal volume and plateau pressure use for acute lung injury from 2000 to present: a systematic literature review.

Authors:  Dharmvir S Jaswal; Janice M Leung; Junfeng Sun; Xizhong Cui; Yan Li; Steven Kern; Judith Welsh; Charles Natanson; Peter Q Eichacker
Journal:  Crit Care Med       Date:  2014-10       Impact factor: 7.598

Review 8.  Biomarkers for the acute respiratory distress syndrome: how to make the diagnosis more precise.

Authors:  M Isabel García-Laorden; José A Lorente; Carlos Flores; Arthur S Slutsky; Jesús Villar
Journal:  Ann Transl Med       Date:  2017-07

9.  Chronic Alcohol Ingestion Impairs Rat Alveolar Macrophage Phagocytosis via Disruption of RAGE Signaling.

Authors:  Bashar S Staitieh; Eduardo E Egea; Xian Fan; Adaugo Amah; David M Guidot
Journal:  Am J Med Sci       Date:  2018-02-01       Impact factor: 2.378

10.  SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care.

Authors:  Clemens Gutmann; Kaloyan Takov; Sean A Burnap; Bhawana Singh; Hashim Ali; Konstantinos Theofilatos; Ella Reed; Maria Hasman; Adam Nabeebaccus; Matthew Fish; Mark Jw McPhail; Kevin O'Gallagher; Lukas E Schmidt; Christian Cassel; Marieke Rienks; Xiaoke Yin; Georg Auzinger; Salvatore Napoli; Salma F Mujib; Francesca Trovato; Barnaby Sanderson; Blair Merrick; Umar Niazi; Mansoor Saqi; Konstantina Dimitrakopoulou; Rafael Fernández-Leiro; Silke Braun; Romy Kronstein-Wiedemann; Katie J Doores; Jonathan D Edgeworth; Ajay M Shah; Stefan R Bornstein; Torsten Tonn; Adrian C Hayday; Mauro Giacca; Manu Shankar-Hari; Manuel Mayr
Journal:  Nat Commun       Date:  2021-06-07       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.